Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC

Video

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® regarding the emergence of cabozantinib (Cabometyx) as a treatment option for patients with renal cell carcinoma and discussed future research around the drug from an abstract on the SWOG 1500 trial (NCT02761057) at the 2021 Genitourinary Cancers Symposium.

Transcription:

From here on out, it’s going to be the infrequent patient that receives sunitinib (Sutent) in the frontline setting, outside of perhaps clinical trials. I think that cabozantinib probably should be the gold standard. The big question that emerges is ‘do we combine cabozantinib with immunotherapy now that we can do that for these patients,’ and I would suggest some pause. I would suggest that perhaps it’s better for us to wait until we have randomized data. To that end, we are moving forward with a clinical trial of cabozantinib plus or minus immunotherapy in patients with papillary kidney cancer within the cooperative groups. Once again, it’s a trial…looking at that combination of agents.

Reference:

Pal SK, Tangen C, Thompson IM, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Presented at: 2021 Genitourinary Cancers Symposium. Abstract 270.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content